bioRxivImmunologyPreprint
High-throughput platforms for genetic perturbation screening using CRISPR/Cas9 in human iPSC-derived macrophages for drug discovery
Matteo Martufi, Eleni Karagianni, Tasos PapanikosiD, Tim G. Ashlin, Aikaterini GeladakiiD, Benedetta Carbone, Katja S. RemlingeriD, Andres Quintero Moreno, William G. PembrokeiD, Charlie Haslam, Nico ZinniD, Denise F. Vlachou, Margarida Almeida, Dimitrios Tsaousis, Stephan GadeiD, Bin Sun, Muhammad Ahmad MaqbooliD, Holger Franken, Frederik ZiebelliD, Alessandro Di Tullio, Lewis Entwistle, Naren SrinivasaniD, Mercedes LoberaiD, Lisa Mohamet
- Citations
- 0
Abstract
Human induced Pluripotent Stem Cell (hiPSC) models have revolutionised drug discovery, offering high translational relevance for recapitulating disease biology and thereby the potential to help reduce drug attrition. Macrophages are pivotal for maintaining tissue homeostasis and orchestrating immune responses; their dysregulation underpins several diseases, including autoinflammatory disorders, neurodegeneration, and cancer. Therapeutically targeting this cell type presents an attractive strategy to simultaneously influence multiple cellular mediators and functions. We have established a scalable, semi-automated, and physiologically relevant hiPSC-derived macrophage model, rigorously characterised through deep comparative multi-omics. We have also integrated our hiPSC-derived macrophage platform with large-scale CRISPR screening workflows designed for parallel genetic interrogation of thousands of gene targets, in both arrayed and pooled formats. In this manuscript, we apply those genetic screening methods to hiPSC-derived macrophages and showcase how genetic perturbations alter pro- and anti-inflammatory transcriptional signatures and significantly impact functional phenotypes in this cell model. This integrated approach allows for the exploration of novel genetic insights linked to causal disease biology, advancing myeloid cell-associated target discovery across a broad spectrum of therapeutic areas.
- organism: human
- assay: bulk RNA-seq
- research focus: drug response / drug discovery
- approach: genetic perturbation / CRISPR
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- SAMHD1 Knockout iPSC model enables high lenti-viral transduction in myeloid cell types
Huinan Li, Maliha Afroze, … Shawn Shafer·bioRxiv·Feb 4, 2025
- A CRISPRi/a platform in iPSC-derived microglia uncovers regulators of disease states
Nina M. Dräger, Sydney M. Sattler, … Martin Kampmann·bioRxiv·Jun 16, 2021
- Differentiation of Human induced Pluripotent Stem Cells to Authentic Macrophages using Fully Defined, Serum Free, Open Source Media
A. Vaughan-Jackson, S. Stodolak, … W. S. James·bioRxiv·Oct 27, 2020
- High throughput CRISPR screening identifies genes involved in macrophage viability and inflammatory pathways
S. Covarrubias, A. Vollmers, … S. Carpenter·bioRxiv·Oct 17, 2019
- Modeling Stimulus-Induced Stress Responses in Microglia-like Cells Using a Commercial iPSC-dCas9-KRAB Line
Devin Saunders, Faraz A. Sultan, … Yanling Wang·bioRxiv·Aug 30, 2025
- A rapid, genetically-tractable human iPSC-derived model for studying tissue-resident macrophage biology in Alzheimer's and other diseases
Hyo Lee, Grace B. Peppler, … Alison Goate·bioRxiv·Oct 12, 2026